Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

PharmAthene third quarter revenue decreases from $6.8 million to $6.2 million

PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2010.

11 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Halpin Foundation-ASN grant advances research in membranous nephropathy

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant.

11 Nov 2010

Portugal research groups awarded Gates Foundation grants

Two research groups in Portugal are to receive Grand Challenges Exploration Grants from the Bill & Melinda Gates Foundation. One of these research teams is led by Miguel Prud-ncio, at the Instituto de Medicina Molecular (IMM), and the other by Miguel Soares, at the Instituto Gulbenkian de Ci-ncia (IGC) together with Henrique Silveira, at the Instituto de Higiene e Medicina Tropical (IHMT).

11 Nov 2010

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Scientists are reporting development of a long-sought method with the potential for getting medication through a biological barrier that surrounds the brain, where it may limit the brain damage caused by stroke. Their approach for sneaking the nerve-protective drug erythropoietin into the brain is medicine's version of the Trojan Horse ploy straight out of ancient Greek legend.

11 Nov 2010

Scientists identify new way to drive dendritic cells from blood monocytes

Dendritic cells, known to be the prime movers of the body's immune response, are still notoriously difficult to study in humans. Samples, which come primarily from bone marrow or lymphoid tissue, are simply too difficult to obtain. But new research at Rockefeller University has shown scientists a way to study "authentic" dendritic cells from mouse monocytes, which are abundant in the blood, a much more accessible source in humans.

11 Nov 2010

SRU Biosystems announces launch of annual Label-free Technology Award

SRU Biosystems, a leader in label-free technologies, announced today the launch of its annual Label-free Technology Award. This year the company will award its newest label-free BIND SCANNER to an academic or non-profit laboratory to support innovative scientific and drug discovery research.

11 Nov 2010

Micromet to offer shares of common stock

Micromet, Inc. announced today that it intends, subject to market and other conditions, to offer shares of its common stock pursuant to an underwriting agreement with Piper Jaffray & Co. Piper Jaffray is acting as sole underwriter for this offering.

10 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

TRU-016 abstracts to be presented at ASH meeting

Emergent BioSolutions Inc. today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia.

10 Nov 2010

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIB study, EMBLEM, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.

10 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Antibody News and Research

Further Reading

PharmAthene third quarter revenue decreases from $6.8 million to $6.2 million

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Halpin Foundation-ASN grant advances research in membranous nephropathy

Portugal research groups awarded Gates Foundation grants

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Scientists identify new way to drive dendritic cells from blood monocytes

SRU Biosystems announces launch of annual Label-free Technology Award

Micromet to offer shares of common stock

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

TRU-016 abstracts to be presented at ASH meeting

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Neogenix awarded $488,958.50 grant under QTDP program

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

Immunologix partners with Genscript to develop human antibody therapeutics

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Research may help develop new therapies for aggressive prostate cancer

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News